Welcome to our dedicated page for Zynex news (Ticker: ZYXI), a resource for investors and traders seeking the latest updates and insights on Zynex stock.
Zynex Inc. (ZYXI) is a leader in non-invasive medical technology, specializing in electrotherapy devices, pain management solutions, and advanced patient monitoring systems. This news hub provides investors and industry professionals with essential updates on the company’s latest developments, regulatory milestones, and strategic initiatives.
Access real-time information on Zynex’s FDA clearances, product innovations, and financial performance. Our curated news collection covers earnings reports, partnership announcements, clinical trial outcomes, and market expansion efforts. Stay informed about developments across Zynex Medical’s therapeutic devices, Monitoring Solutions’ cardiac technologies, and Neurodiagnostics’ advancements in neurological care.
This resource is designed for those tracking Zynex’s progress in bringing clinically validated medical devices to market. Discover updates on key focus areas including TENS therapy improvements, laser-based monitoring innovations, and compliance with global medical standards. Bookmark this page for streamlined access to press releases, analyst insights, and objective reporting on Zynex’s role in shaping healthcare technology.
Zynex, Inc. (NASDAQ: ZYXI) announced the submission of a 510(k) application to the FDA for its CM-1600 fluid monitoring system, enhancing the existing CM-1500 model. This next-generation device features wireless connectivity and aims to optimize fluid management in patients at risk of hemorrhagic events. CEO Thomas Sandgaard emphasized its potential for improved patient care. The FDA submission is a critical step in advancing the technology, which promises superior accuracy in monitoring before, during, and after surgeries.
Zynex (NASDAQ: ZYXI) announced the acquisition of Kestrel Labs for approximately $31 million, finalized on December 22, 2021. The deal comprises $16 million in cash and $15 million in Zynex stock. Kestrel Labs specializes in laser-based patient monitoring technologies, including the NiCO CO-Oximeter and HemeOx, both pending FDA clearance. The acquisition aims to enhance Zynex's noninvasive monitoring portfolio, potentially leading to improved patient care by offering continuous and accurate hemoglobin monitoring.
Zynex (NASDAQ: ZYXI) has commenced enrollments for a hemodialysis clinical trial using its CM-1500 fluid monitoring system, which received FDA clearance in February 2020. Conducted at DaVita Clinical Research clinics, the trial aims to assess changes in the device's patented Relative Index during hemodialysis. This initiative seeks to refine Zynex's medical technology and advance its monitoring division. The study targets operating and recovery rooms where fluid balance is crucial, expected to complete enrollments by Q1 2022.
ENGLEWOOD, Colo., Nov. 24, 2021 /PRNewswire/ -- Zynex, a medical technology company, announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. The event will feature presentations from November 22 to December 2, 2021, accessible to registered attendees. One-on-one meetings will take place from November 29 to December 2, with requests managed through Piper Sandler. Zynex specializes in non-invasive devices for pain management and rehabilitation, including its NeuroMove device for stroke recovery.
Zynex, Inc. (NASDAQ: ZYXI) has been recognized as the 7th fastest-growing medical device company in revenue growth in the U.S. and Canada according to Deloitte's 2021 Technology Fast 500. The company reported a staggering 242% revenue increase from 2017 to 2020, culminating in $80.1 million in 2020. For 2021, Zynex estimates its revenue will reach between $130.0 million and $133.0 million. This accolade highlights Zynex’s commitment to innovation and growth in the medical technology sector.
Zynex, Inc. (NASDAQ: ZYXI) has declared a one-time special cash dividend of $0.10 per share and a 10% stock dividend. These dividends are payable to all common stockholders of record as of the close of business on January 6, 2022, with payments expected on or about January 21, 2022. The cash dividend is projected to total approximately $3.5 million, while the stock dividend will issue about 3.5 million additional shares. CEO Thomas Sandgaard emphasized the company's strong financial position and commitment to rewarding shareholders.
Zynex reported strong financial results for Q3 2021, with revenue increasing 74% year-over-year to $34.8 million. The company achieved a record net income of $6.1 million, translating to a diluted EPS of $0.17. Adjusted EBITDA was reported at $9.3 million. Working capital grew by 13% to $59.6 million, with cash on hand reaching $35.4 million. The company anticipates Q4 revenue between $40.0 and $43.0 million and a full-year revenue estimate of $130.0 to $133.0 million, reflecting a growth of 62% to 66% compared to 2020.
Zynex, a medical technology company, will host a webcast for its 2021 third quarter earnings on November 2, 2021, at 2:15 PM MT (4:15 PM ET). The company specializes in non-invasive medical devices for pain management, stroke rehabilitation, and more. Interested participants can register for the webcast through the provided link. Founded in 1996, Zynex focuses on innovative solutions, including the NeuroMove device for stroke recovery. For more details, visit Zynex.com.
Zynex, Inc. (NASDAQ: ZYXI) announced a strong performance for Q3 2021, reporting a 70% year-over-year order growth and projecting Q3 revenue between $34.5 million and $36 million. The company has increased its Adjusted EBITDA estimate to $9 million to $10 million, up from a prior estimate of $5 million to $6 million. For the full year, Zynex estimates revenue between $130 million and $137.5 million, reflecting an increase of 62% to 72% compared to the previous year. This growth supports Zynex's strategy to provide non-opioid pain management solutions.
FAQ
What is the current stock price of Zynex (ZYXI)?
What is the market cap of Zynex (ZYXI)?
